Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iCP-RFs + Cas9
- Development stage
- Preclinical
- Lead developer
- Cellivery Therapeutics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Recombinant Proteins and Enzymes, Cell Therapies
- Administration
- Intravenous
01
Overview
iCP-RFs + Cas9 (also known as iCP-Cas9) is an experimental therapeutic candidate developed by Cellivery Therapeutics that combines gene editing and cell reprogramming capabilities. The product utilizes the company's proprietary Tissue-Permeable Signal Transduction Therapy (TSDT) platform, which employs an Advanced Macromolecule Transduction Domain (aMTD) to facilitate the direct intracellular delivery of the Cas9 nuclease and various reprogramming factors (RFs). Unlike conventional gene editing approaches that rely on viral vectors or lipid nanoparticles to deliver genetic material (DNA or mRNA), iCP-RFs + Cas9 delivers functional proteins directly into the cytoplasm and nucleus of target cells. This protein-based delivery method is designed to minimize off-target effects and genomic integration risks associated with nucleic acid delivery. The technology is intended for applications in therapeutic gene editing and the generation of induced pluripotent stem cells (iPSCs) for regenerative medicine, although specific clinical indications have not yet been disclosed.
- Other names
- iCP-RFs + Cas9
02
Targets
CRISPR target site
Beyond the preview
Go deeper on iCP-RFs + Cas9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCP-RFs + Cas9.